{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:08:36Z","timestamp":1793236116858,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Young Talent of Lifting engineering for Science and Technology in Shandong","award":["SDAST2024QTA032"],"award-info":[{"award-number":["SDAST2024QTA032"]}]},{"name":"Wu Jieping Medical Foundation Clinical Research Special Fund","award":["320.6750.2024-17-41"],"award-info":[{"award-number":["320.6750.2024-17-41"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-37540-9","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T18:03:45Z","timestamp":1769709825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["TIPE2 serves as a favorable prognostic biomarker and suppresses cholangiocarcinoma progression by targeting RAC1-mediated integrin \u03b1v\u03b26 trafficking"],"prefix":"10.1038","volume":"16","author":[{"given":"Shasha","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zequn","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"37540_CR1","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava, N. & Gores, G. J. Cholangiocarcinoma. Lancet 383, 2168\u20132179. https:\/\/doi.org\/10.1016\/S0140-6736(13)61903-0 (2014).","journal-title":"Lancet"},{"key":"37540_CR2","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1136\/gutjnl-2011-301748","volume":"61","author":"SA Khan","year":"2012","unstructured":"Khan, S. A. et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: An update. Gut 61, 1657\u20131669. https:\/\/doi.org\/10.1136\/gutjnl-2011-301748 (2012).","journal-title":"Gut"},{"key":"37540_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s12885-023-11040-9","volume":"23","author":"S Zhou","year":"2023","unstructured":"Zhou, S. et al. Cancer-specific survival in patients with cholangiocarcinoma after radical surgery: a Novel, dynamic nomogram based on clinicopathological features and serum markers. BMC Cancer 23, 533. https:\/\/doi.org\/10.1186\/s12885-023-11040-9 (2023).","journal-title":"BMC Cancer"},{"key":"37540_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/cncr.34552","volume":"129","author":"Y Zheng","year":"2023","unstructured":"Zheng, Y. et al. The clinicopathological significance and relapse predictive role of tumor microenvironment of intrahepatic cholangiocarcinoma after radical surgery. Cancer 129, 393\u2013404. https:\/\/doi.org\/10.1002\/cncr.34552 (2023).","journal-title":"Cancer"},{"key":"37540_CR5","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/cncr.34639","volume":"129","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. A novel prognostic system combining carbonic anhydrase II and preoperative CA19-9 for intrahepatic cholangiocarcinoma after curative resection. Cancer 129, 1030\u20131040. https:\/\/doi.org\/10.1002\/cncr.34639 (2023).","journal-title":"Cancer"},{"key":"37540_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.21037\/hbsn-23-255","volume":"12","author":"I Amygdalos","year":"2023","unstructured":"Amygdalos, I., Neumann, U. P. & Lang, S. A. Targeted therapies in cholangiocarcinoma: light at the end of the tunnel?. Hepatobiliary Surg. Nutr. 12, 631\u2013633. https:\/\/doi.org\/10.21037\/hbsn-23-255 (2023).","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"37540_CR7","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1136\/gutjnl-2022-327099","volume":"71","author":"RIR Macias","year":"2022","unstructured":"Macias, R. I. R. et al. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut 71, 1669\u20131683. https:\/\/doi.org\/10.1136\/gutjnl-2022-327099 (2022).","journal-title":"Gut"},{"issue":"Suppl 1","key":"37540_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S0140-6736(15)60409-3","volume":"385","author":"B Stephenson","year":"2015","unstructured":"Stephenson, B. et al. Quantitative assessment of the cell surface proteome to identify novel therapeutic targets in cholangiocarcinoma. Lancet 385(Suppl 1), 94. https:\/\/doi.org\/10.1016\/S0140-6736(15)60409-3 (2015).","journal-title":"Lancet"},{"key":"37540_CR9","doi-asserted-by":"publisher","first-page":"919","DOI":"10.14670\/HH-11-977","volume":"33","author":"Z Li","year":"2018","unstructured":"Li, Z., Jia, W., Niu, J. & Zhang, L. Understanding the roles of negative immune regulator TIPE2 in different diseases and tumourigenesis. Histol. Histopathol. 33, 919\u2013928. https:\/\/doi.org\/10.14670\/HH-11-977 (2018).","journal-title":"Histol. Histopathol."},{"key":"37540_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nsmb.1522","volume":"16","author":"X Zhang","year":"2009","unstructured":"Zhang, X. et al. Crystal structure of TIPE2 provides insights into immune homeostasis. Nat. Struct. Mol. Biol. 16, 89\u201390. https:\/\/doi.org\/10.1038\/nsmb.1522 (2009).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"37540_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cell.2008.03.026","volume":"133","author":"H Sun","year":"2008","unstructured":"Sun, H. et al. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell 133, 415\u2013426. https:\/\/doi.org\/10.1016\/j.cell.2008.03.026 (2008).","journal-title":"Cell"},{"key":"37540_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110514","volume":"121","author":"J Gao","year":"2023","unstructured":"Gao, J., Zhang, H. & Zhang, F. Research progress of TIPE2 in immune-related diseases. Int. Immunopharmacol. 121, 110514. https:\/\/doi.org\/10.1016\/j.intimp.2023.110514 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"37540_CR13","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.canlet.2018.06.017","volume":"432","author":"G Padmavathi","year":"2018","unstructured":"Padmavathi, G. et al. Novel tumor necrosis factor-alpha induced protein eight (TNFAIP8\/TIPE) family: Functions and downstream targets involved in cancer progression. Cancer Lett. 432, 260\u2013271. https:\/\/doi.org\/10.1016\/j.canlet.2018.06.017 (2018).","journal-title":"Cancer Lett."},{"key":"37540_CR14","doi-asserted-by":"publisher","first-page":"1610282","DOI":"10.3389\/pore.2022.1610282","volume":"28","author":"Y Jiang","year":"2022","unstructured":"Jiang, Y. et al. A novel prognostic factor TIPE2 in bladder cancer. Pathol. Oncol. Res. POR 28, 1610282. https:\/\/doi.org\/10.3389\/pore.2022.1610282 (2022).","journal-title":"Pathol. Oncol. Res. POR"},{"key":"37540_CR15","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/jcb.25068","volume":"116","author":"Q Zhao","year":"2015","unstructured":"Zhao, Q. et al. Tumor necrosis factor-alpha-induced protein-8 like-2 (TIPE2) upregulates p27 to decrease gastic cancer cell proliferation. J. Cell. Biochem. 116, 1121\u20131129. https:\/\/doi.org\/10.1002\/jcb.25068 (2015).","journal-title":"J. Cell. Biochem."},{"key":"37540_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3892\/ijo.2014.2725","volume":"46","author":"YH Zhang","year":"2015","unstructured":"Zhang, Y. H. et al. TIPE2 inhibits TNF-alpha-induced hepatocellular carcinoma cell metastasis via Erk1\/2 downregulation and NF-kappaB activation. Int. J. Oncol. 46, 254\u2013264. https:\/\/doi.org\/10.3892\/ijo.2014.2725 (2015).","journal-title":"Int. J. Oncol."},{"key":"37540_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/1476-4598-12-149","volume":"12","author":"X Cao","year":"2013","unstructured":"Cao, X. et al. Human tumor necrosis factor (TNF)-alpha-induced protein 8-like 2 suppresses hepatocellular carcinoma metastasis through inhibiting Rac1. Mol. Cancer 12, 149. https:\/\/doi.org\/10.1186\/1476-4598-12-149 (2013).","journal-title":"Mol. Cancer"},{"key":"37540_CR18","doi-asserted-by":"publisher","first-page":"62224","DOI":"10.18632\/oncotarget.11406","volume":"7","author":"Z Li","year":"2016","unstructured":"Li, Z. et al. TIPE2 suppresses angiogenesis and non-small cell lung cancer (NSCLC) invasiveness via inhibiting Rac1 activation and VEGF expression. Oncotarget 7, 62224\u201362239. https:\/\/doi.org\/10.18632\/oncotarget.11406 (2016).","journal-title":"Oncotarget"},{"key":"37540_CR19","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/s0092-8674(02)00971-6","volume":"110","author":"RO Hynes","year":"2002","unstructured":"Hynes, R. O. Integrins: bidirectional, allosteric signaling machines. Cell 110, 673\u2013687. https:\/\/doi.org\/10.1016\/s0092-8674(02)00971-6 (2002).","journal-title":"Cell"},{"key":"37540_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","volume":"18","author":"H Hamidi","year":"2018","unstructured":"Hamidi, H. & Ivaska, J. Every step of the way: integrins in cancer progression and metastasis. Nat. Rev. Cancer 18, 533\u2013548. https:\/\/doi.org\/10.1038\/s41568-018-0038-z (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"37540_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.canlet.2017.06.012","volume":"403","author":"J Niu","year":"2017","unstructured":"Niu, J. & Li, Z. The roles of integrin alphavbeta6 in cancer. Cancer Lett. 403, 128\u2013137. https:\/\/doi.org\/10.1016\/j.canlet.2017.06.012 (2017).","journal-title":"Cancer Lett."},{"key":"37540_CR22","doi-asserted-by":"publisher","first-page":"30081","DOI":"10.1038\/srep30081","volume":"6","author":"Z Li","year":"2016","unstructured":"Li, Z. et al. Integrin beta6 serves as an immunohistochemical marker for lymph node metastasis and promotes cell invasiveness in cholangiocarcinoma. Sci. Rep. 6, 30081. https:\/\/doi.org\/10.1038\/srep30081 (2016).","journal-title":"Sci. Rep."},{"key":"37540_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2011.06.025","volume":"311","author":"J Wang","year":"2011","unstructured":"Wang, J. et al. PKC promotes the migration of colon cancer cells by regulating the internalization and recycling of integrin alphavbeta6. Cancer Lett. 311, 38\u201347. https:\/\/doi.org\/10.1016\/j.canlet.2011.06.025 (2011).","journal-title":"Cancer Lett."},{"key":"37540_CR24","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1053\/j.gastro.2023.02.045","volume":"164","author":"SY Cho","year":"2023","unstructured":"Cho, S. Y. et al. Refining classification of cholangiocarcinoma subtypes via proteogenomic integration reveals new therapeutic prospects. Gastroenterology 164, 1293\u20131309. https:\/\/doi.org\/10.1053\/j.gastro.2023.02.045 (2023).","journal-title":"Gastroenterology"},{"key":"37540_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.21037\/hbsn-23-215","volume":"12","author":"RIR Macias","year":"2023","unstructured":"Macias, R. I. R., Rimassa, L. & Lamarca, A. The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment. Hepatobiliary Surg. Nutr. 12, 457\u2013461. https:\/\/doi.org\/10.21037\/hbsn-23-215 (2023).","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"37540_CR26","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.4049\/jimmunol.1300053","volume":"191","author":"Y Lou","year":"2013","unstructured":"Lou, Y. et al. Enhanced atherosclerosis in TIPE2-deficient mice is associated with increased macrophage responses to oxidized low-density lipoprotein. J. Immunol. 191, 4849\u20134857. https:\/\/doi.org\/10.4049\/jimmunol.1300053 (2013).","journal-title":"J. Immunol."},{"key":"37540_CR27","doi-asserted-by":"publisher","first-page":"15413","DOI":"10.1073\/pnas.1204525109","volume":"109","author":"Z Wang","year":"2012","unstructured":"Wang, Z. et al. TIPE2 protein serves as a negative regulator of phagocytosis and oxidative burst during infection. Proc. Natl. Acad. Sci. U.S.A. 109, 15413\u201315418. https:\/\/doi.org\/10.1073\/pnas.1204525109 (2012).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"37540_CR28","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.molcel.2012.01.006","volume":"45","author":"Y Gus-Brautbar","year":"2012","unstructured":"Gus-Brautbar, Y. et al. The anti-inflammatory TIPE2 is an inhibitor of the oncogenic Ras. Mol. Cell 45, 610\u2013618. https:\/\/doi.org\/10.1016\/j.molcel.2012.01.006 (2012).","journal-title":"Mol. Cell"},{"key":"37540_CR29","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.molimm.2011.03.001","volume":"48","author":"L Zhang","year":"2011","unstructured":"Zhang, L. et al. The unique expression profile of human TIPE2 suggests new functions beyond its role in immune regulation. Mol. Immunol. 48, 1209\u20131215. https:\/\/doi.org\/10.1016\/j.molimm.2011.03.001 (2011).","journal-title":"Mol. Immunol."},{"key":"37540_CR30","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1016\/j.molimm.2010.06.016","volume":"47","author":"G Zhang","year":"2010","unstructured":"Zhang, G. et al. Tissue-specific expression of TIPE2 provides insights into its function. Mol. Immunol. 47, 2435\u20132442. https:\/\/doi.org\/10.1016\/j.molimm.2010.06.016 (2010).","journal-title":"Mol. Immunol."},{"key":"37540_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13578-018-0247-x","volume":"8","author":"W Jia","year":"2018","unstructured":"Jia, W. et al. TIPE2 acts as a biomarker for tumor aggressiveness and suppresses cell invasiveness in papillary thyroid cancer (PTC). Cell Biosci. 8, 49. https:\/\/doi.org\/10.1186\/s13578-018-0247-x (2018).","journal-title":"Cell Biosci."},{"key":"37540_CR32","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris, D. et al. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CE A Cancer J. Clinic. 73, 198\u2013222. https:\/\/doi.org\/10.3322\/caac.21759 (2023).","journal-title":"CE A Cancer J. Clinic."},{"key":"37540_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2022.101851","volume":"44","author":"ZJ Brown","year":"2022","unstructured":"Brown, Z. J., Patwardhan, S., Bean, J. & Pawlik, T. M. Molecular diagnostics and biomarkers in cholangiocarcinoma. Surg. Oncol. 44, 101851. https:\/\/doi.org\/10.1016\/j.suronc.2022.101851 (2022).","journal-title":"Surg. Oncol."},{"key":"37540_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/cncr.34541","volume":"129","author":"KC Ohaegbulam","year":"2023","unstructured":"Ohaegbulam, K. C. et al. The multidisciplinary management of cholangiocarcinoma. Cancer 129, 184\u2013214. https:\/\/doi.org\/10.1002\/cncr.34541 (2023).","journal-title":"Cancer"},{"key":"37540_CR35","doi-asserted-by":"publisher","first-page":"153303382311893","DOI":"10.1177\/15330338231189399","volume":"22","author":"Y Lian","year":"2023","unstructured":"Lian, Y. et al. Review and application of integrin alpha v beta 6 in the diagnosis and treatment of cholangiocarcinoma and pancreatic ductal adenocarcinoma. Technol. Cancer Res. Treat. 22, 15330338231189400. https:\/\/doi.org\/10.1177\/15330338231189399 (2023).","journal-title":"Technol. Cancer Res. Treat."},{"key":"37540_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.molimm.2011.08.006","volume":"49","author":"Y Lou","year":"2011","unstructured":"Lou, Y. & Liu, S. The TIPE (TNFAIP8) family in inflammation, immunity, and cancer. Mol. Immunol. 49, 4\u20137. https:\/\/doi.org\/10.1016\/j.molimm.2011.08.006 (2011).","journal-title":"Mol. Immunol."},{"key":"37540_CR37","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/cmi.2017.4","volume":"14","author":"JR Goldsmith","year":"2017","unstructured":"Goldsmith, J. R., Fayngerts, S. & Chen, Y. H. Regulation of inflammation and tumorigenesis by the TIPE family of phospholipid transfer proteins. Cell. Mol. Immunol. 14, 482\u2013487. https:\/\/doi.org\/10.1038\/cmi.2017.4 (2017).","journal-title":"Cell. Mol. Immunol."},{"key":"37540_CR38","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/humrep\/deaa062","volume":"35","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. TIPE2 inhibits the migration and invasion of endometrial cells by targeting beta-catenin to reverse epithelial-mesenchymal transition. Hum. Reprod. 35, 1377\u20131390. https:\/\/doi.org\/10.1093\/humrep\/deaa062 (2020).","journal-title":"Hum. Reprod."},{"key":"37540_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3727\/096504016X14666990347356","volume":"24","author":"ZJ Liu","year":"2016","unstructured":"Liu, Z. J., Liu, H. L., Zhou, H. C. & Wang, G. C. TIPE2 inhibits hypoxia-induced Wnt\/beta-catenin pathway activation and EMT in glioma cells. Oncol. Res. 24, 255\u2013261. https:\/\/doi.org\/10.3727\/096504016X14666990347356 (2016).","journal-title":"Oncol. Res."},{"key":"37540_CR40","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1515\/biol-2019-0059","volume":"14","author":"LQ Huang","year":"2019","unstructured":"Huang, L. Q., Zheng, B. & He, Y. Immune negative regulator TIPE2 inhibits cervical squamous cancer progression through Erk1\/2 signaling. Open Life Sci. 14, 528\u2013536. https:\/\/doi.org\/10.1515\/biol-2019-0059 (2019).","journal-title":"Open Life Sci."},{"key":"37540_CR41","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.molimm.2017.03.007","volume":"85","author":"Z Zhang","year":"2017","unstructured":"Zhang, Z., Liu, L., Cao, S., Zhu, Y. & Mei, Q. Gene delivery of TIPE2 inhibits breast cancer development and metastasis via CD8(+) T and NK cell-mediated antitumor responses. Mol. Immunol. 85, 230\u2013237. https:\/\/doi.org\/10.1016\/j.molimm.2017.03.007 (2017).","journal-title":"Mol. Immunol."},{"key":"37540_CR42","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.18632\/aging.204529","volume":"15","author":"S Xu","year":"2023","unstructured":"Xu, S. et al. TIPE2 acts as a tumor suppressor and correlates with tumor microenvironment immunity in epithelial ovarian cancer. Aging 15, 1052\u20131073. https:\/\/doi.org\/10.18632\/aging.204529 (2023).","journal-title":"Aging"},{"key":"37540_CR43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3892\/ol.2013.1388","volume":"6","author":"Z Zhang","year":"2013","unstructured":"Zhang, Z., Qi, H., Hou, S. & Jin, X. TIPE2 mRNA overexpression correlates with TNM staging in renal cell carcinoma tissues. Oncol. Lett. 6, 571\u2013575. https:\/\/doi.org\/10.3892\/ol.2013.1388 (2013).","journal-title":"Oncol. Lett."},{"key":"37540_CR44","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3233\/CBM-140402","volume":"14","author":"XM Li","year":"2014","unstructured":"Li, X. M. et al. A novel inflammatory regulator TIPE2 inhibits TLR4-mediated development of colon cancer via caspase-8. Cancer biomarkers Sect. A Disease Mark. 14, 233\u2013240. https:\/\/doi.org\/10.3233\/CBM-140402 (2014).","journal-title":"Cancer biomarkers Sect. A Disease Mark."},{"key":"37540_CR45","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12964-023-01264-4","volume":"21","author":"S Li","year":"2023","unstructured":"Li, S., Sampson, C., Liu, C., Piao, H. L. & Liu, H. X. Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities. Cell Commun. Signal 21, 266. https:\/\/doi.org\/10.1186\/s12964-023-01264-4 (2023).","journal-title":"Cell Commun. Signal"},{"key":"37540_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012346","author":"E Brzozowska","year":"2022","unstructured":"Brzozowska, E. & Deshmukh, S. Integrin Alpha v Beta 6 (alphavbeta6) and its implications in cancer treatment. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms232012346 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"37540_CR47","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/ncb2455","volume":"14","author":"WH Yang","year":"2012","unstructured":"Yang, W. H. et al. RAC1 activation mediates Twist1-induced cancer cell migration. Nat. Cell Biol. 14, 366\u2013374. https:\/\/doi.org\/10.1038\/ncb2455 (2012).","journal-title":"Nat. Cell Biol."},{"key":"37540_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.770997","volume":"11","author":"Z Li","year":"2021","unstructured":"Li, Z. et al. Integrin-beta6 serves as a potential prognostic serum biomarker for gastric cancer. Front. Oncol. 11, 770997. https:\/\/doi.org\/10.3389\/fonc.2021.770997 (2021).","journal-title":"Front. Oncol."},{"key":"37540_CR49","doi-asserted-by":"publisher","first-page":"755","DOI":"10.4049\/jimmunol.2300433","volume":"212","author":"L Xu","year":"2024","unstructured":"Xu, L., Pan, F. & Guo, Z. TIPE2: A candidate for targeting antitumor immunotherapy. J. Immunol. 212, 755\u2013763. https:\/\/doi.org\/10.4049\/jimmunol.2300433 (2024).","journal-title":"J. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37540-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T09:19:32Z","timestamp":1771319972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37540-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["37540"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-37540-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"21 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6638"}}